Orexigen Therapeutics, Inc. (NASDAQ:OREX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity.

Recs

0
Player Avatar ChartMyStock (31.50) Submitted: 7/17/2012 12:15:01 PM : Underperform Start Price: $7.35 OREX Score: +35.11

Speculation undeserving.

Featured Broker Partners


Advertisement